AIM To investigate the clinicopathological significance of progesterone receptor membrane component 1(PGRMC1) and PGRMC2 in hepatocellular carcinoma(HCC). METHODS We performed immunohistochemical staining to evaluate ...AIM To investigate the clinicopathological significance of progesterone receptor membrane component 1(PGRMC1) and PGRMC2 in hepatocellular carcinoma(HCC). METHODS We performed immunohistochemical staining to evaluate the estrogen receptor(ER), progesterone receptor(PR), PGRMC1, and PGRMC2 in a clinical cohort consisting of 89 paired HCC and non-tumor liver samples. We also analyzed HCC data(n = 373) from The Cancer Genome Atlas(TCGA). We correlated the expression status of PGRMC1 and PGRMC2 with clinicopathological indicators and the clinical outcomes of the HCC patients. We knocked down or overexpressed PGRMC1 in HCC cell lines to evaluate its biological significance in HCC cell proliferation, differentiation, migration, and invasion. RESULTS We found that few HCC cases expressed ER(5.6%) and PR(4.5%). In contrast, most HCC cases expressed PGRMC1(89.9%) and PGRMC2(100%). PGRMC1 and PGRMC2 exhibited significantly lower expression in tumor tissue than in non-tumor tissue(P < 0.001). Lower PGRMC1 expression in HCC was significantly associated with higher serum alpha-fetoprotein expression(P = 0.004), poorer tumor differentiation(P = 0.045) and liver capsule penetration(P = 0.038). Low PGRMC1 expression was an independent predictor for worse disease-free survival(P = 0.002, HR = 2.384,CI: 1.377-4.128) in our cases, as well as in the TCGA cohort(P < 0.001, HR = 2.857, CI: 1.781-4.584). The expression of PGRMC2 did not relate to patient outcome. PGRMC1 knockdown promoted a poorly differentiated phenotype and proliferation of HCC cells in vitro, while PGRMC1 overexpression caused the opposite effects.CONCLUSION PGRMC1 is a non-classical hormonal receptor that negatively regulates hepatocarcinogenesis. PGRMC1 down-regulation is associated with progression of HCC and is a poor prognostic indicator.展开更多
Five types of superparamagnetic iron oxide （SPIO）,i.e. Ferumoxides （Feridex？ Ⅳ, Berlex Laboratories）,Fe r u c a r b o t ra n （ Re s ov i s t？, B aye r H e a l t h c a re ） ,Ferumoxtran-10 （AMI-227 or Code-72...Five types of superparamagnetic iron oxide （SPIO）,i.e. Ferumoxides （Feridex？ Ⅳ, Berlex Laboratories）,Fe r u c a r b o t ra n （ Re s ov i s t？, B aye r H e a l t h c a re ） ,Ferumoxtran-10 （AMI-227 or Code-7227, Combidex？, AMAG Pharma; Sinerem？, Guerbet）, NC100150（Clariscan？, Nycomed,） and （VSOP C184, Ferropharm）have been designed and clinically tested as magneticresonance contrast agents. However, until nowResovist？ is current available in only a few countries.The other four agents have been stopped for furtherdevelopment or withdrawn from the market. AnotherSPIO agent Ferumoxytol （Feraheme） is approved forthe treatment of iron deficiency in adult chronic kidneydisease patients. Ferumoxytol is comprised of ironoxide particles surrounded by a carbohydrate coat, andit is being explored as a potential imaging approach forevaluating lymph nodes and certain liver tumors.展开更多
目的:探讨细胞外的热休克蛋白7 0及H S P70肽复合物(h e a t s h o c k p r o t e i n 70/peptide complexes,HSP70/HSP70-PCs)对肝癌细胞HepG2缺氧诱导因子1(hypoxiainduciblefactor-1,HIF-1)、葡萄糖转运蛋白1(glucose transporter 1,...目的:探讨细胞外的热休克蛋白7 0及H S P70肽复合物(h e a t s h o c k p r o t e i n 70/peptide complexes,HSP70/HSP70-PCs)对肝癌细胞HepG2缺氧诱导因子1(hypoxiainduciblefactor-1,HIF-1)、葡萄糖转运蛋白1(glucose transporter 1,Glut1)、血管内皮生长因子(vascular endothelial growth factor,VEGF)表达的影响及可能机制.方法:将肝癌细胞分为3组:正常对照组、细胞外HSP70/HSP70-PCs诱导实验组(终浓度2g/mL)、细胞外HSP70/HSP70-PCs+siRNA转染组.应用Real-time RT-PCR与Western blot法检测HIF-1、Glut1和VEGF的表达变化.结果:细胞外HSP70/HSP70-PCs诱导实验组HIF-1、VEGF与Glut1蛋白表达显著升高,与对照组相比有显著差异(P<0.05),表明细胞外HSP70/HSP70-PCs促进肝癌细胞的HIF-1、Glut1和VEGF表达;应用siRNA阻断HIF-1后,细胞外HSP70/HSP70-PCs对Glut1和VEGF的上调表达作用消失,与对照组相比有明显差异(P<0.05).结论:细胞外HSP70/HSP70-PCs可以上调肝癌细胞HepG2中Glut1和VEGF表达,并且这一作用是通过HIF-1来实现的.展开更多
基金Supported by the Ministry of Science and Technology,No.NSC102-2320-B-006-011.,No.MOST103-2320-B-006-021-MY2,and No.MOST105-2320-B-006-033 to Tsai HWNational Cheng Kung University Hospital,Taiwan,No.NCKUH-10406002 and No.NCKUH-10509001 to Tsai HW
文摘AIM To investigate the clinicopathological significance of progesterone receptor membrane component 1(PGRMC1) and PGRMC2 in hepatocellular carcinoma(HCC). METHODS We performed immunohistochemical staining to evaluate the estrogen receptor(ER), progesterone receptor(PR), PGRMC1, and PGRMC2 in a clinical cohort consisting of 89 paired HCC and non-tumor liver samples. We also analyzed HCC data(n = 373) from The Cancer Genome Atlas(TCGA). We correlated the expression status of PGRMC1 and PGRMC2 with clinicopathological indicators and the clinical outcomes of the HCC patients. We knocked down or overexpressed PGRMC1 in HCC cell lines to evaluate its biological significance in HCC cell proliferation, differentiation, migration, and invasion. RESULTS We found that few HCC cases expressed ER(5.6%) and PR(4.5%). In contrast, most HCC cases expressed PGRMC1(89.9%) and PGRMC2(100%). PGRMC1 and PGRMC2 exhibited significantly lower expression in tumor tissue than in non-tumor tissue(P < 0.001). Lower PGRMC1 expression in HCC was significantly associated with higher serum alpha-fetoprotein expression(P = 0.004), poorer tumor differentiation(P = 0.045) and liver capsule penetration(P = 0.038). Low PGRMC1 expression was an independent predictor for worse disease-free survival(P = 0.002, HR = 2.384,CI: 1.377-4.128) in our cases, as well as in the TCGA cohort(P < 0.001, HR = 2.857, CI: 1.781-4.584). The expression of PGRMC2 did not relate to patient outcome. PGRMC1 knockdown promoted a poorly differentiated phenotype and proliferation of HCC cells in vitro, while PGRMC1 overexpression caused the opposite effects.CONCLUSION PGRMC1 is a non-classical hormonal receptor that negatively regulates hepatocarcinogenesis. PGRMC1 down-regulation is associated with progression of HCC and is a poor prognostic indicator.
文摘Five types of superparamagnetic iron oxide （SPIO）,i.e. Ferumoxides （Feridex？ Ⅳ, Berlex Laboratories）,Fe r u c a r b o t ra n （ Re s ov i s t？, B aye r H e a l t h c a re ） ,Ferumoxtran-10 （AMI-227 or Code-7227, Combidex？, AMAG Pharma; Sinerem？, Guerbet）, NC100150（Clariscan？, Nycomed,） and （VSOP C184, Ferropharm）have been designed and clinically tested as magneticresonance contrast agents. However, until nowResovist？ is current available in only a few countries.The other four agents have been stopped for furtherdevelopment or withdrawn from the market. AnotherSPIO agent Ferumoxytol （Feraheme） is approved forthe treatment of iron deficiency in adult chronic kidneydisease patients. Ferumoxytol is comprised of ironoxide particles surrounded by a carbohydrate coat, andit is being explored as a potential imaging approach forevaluating lymph nodes and certain liver tumors.
文摘目的:探讨细胞外的热休克蛋白7 0及H S P70肽复合物(h e a t s h o c k p r o t e i n 70/peptide complexes,HSP70/HSP70-PCs)对肝癌细胞HepG2缺氧诱导因子1(hypoxiainduciblefactor-1,HIF-1)、葡萄糖转运蛋白1(glucose transporter 1,Glut1)、血管内皮生长因子(vascular endothelial growth factor,VEGF)表达的影响及可能机制.方法:将肝癌细胞分为3组:正常对照组、细胞外HSP70/HSP70-PCs诱导实验组(终浓度2g/mL)、细胞外HSP70/HSP70-PCs+siRNA转染组.应用Real-time RT-PCR与Western blot法检测HIF-1、Glut1和VEGF的表达变化.结果:细胞外HSP70/HSP70-PCs诱导实验组HIF-1、VEGF与Glut1蛋白表达显著升高,与对照组相比有显著差异(P<0.05),表明细胞外HSP70/HSP70-PCs促进肝癌细胞的HIF-1、Glut1和VEGF表达;应用siRNA阻断HIF-1后,细胞外HSP70/HSP70-PCs对Glut1和VEGF的上调表达作用消失,与对照组相比有明显差异(P<0.05).结论:细胞外HSP70/HSP70-PCs可以上调肝癌细胞HepG2中Glut1和VEGF表达,并且这一作用是通过HIF-1来实现的.
